Get the Stockscreener App
16.47
0.12%
-0.02
Imagenebio Inc stock is traded at $16.47, with a volume of 288.
It is down -0.12% in the last 24 hours and up +0.00% over the past month.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
See More
Previous Close:
$16.49
Open:
$16.47
24h Volume:
288
Relative Volume:
0.08
Market Cap:
$185.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.72%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.47
$16.47
1-Week Range:
$15.03
$17.96
52-Week Range:
$15.03
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Name
Imagenebio Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
16.47 | 185.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.82 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.27 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
678.80 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.00 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Imagenebio Inc Stock (IMA) Latest News
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio Approves 2025 Inducement Plan for Employees - The Globe and Mail
ImageneBio board approves 2025 inducement plan for new employee equity awards - Investing.com Australia
ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent - AInvest
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ImageneBio Grants Massive $9.6M Equity Package: New CEO Gets 436K Stock Options, 153K RSUs - Stock Titan
Imagenebio shares rise 7.26% premarket after insider bought shares worth $7.999.924. - AInvest
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025 - AInvest
Ikena Oncology Completes Merger, Becomes ImageneBio, Inc. - The Globe and Mail
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) - MarketScreener
ImageneBio Appoints Kristin Yarema as CEO, Merges with Ikena Oncology, Raises $75M - AInvest
ImageneBio Launches on Nasdaq Following Merger, Raises $75M for Skin Treatment Development - CTOL Digital Solutions
Ikena Oncology shares fall 2.03% after-hours following acquisition by Inmagene Biopharmaceuticals. - AInvest
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - MSN
Ikena Oncology Completes Merger with Inmagene Biopharmaceuticals - TipRanks
ImageneBio's Strategic Rebirth: A Catalyst for Long-Term Shareholder Value in the Atopic Dermatitis Market - AInvest
Inmagene Biopharmaceuticals Announces Completion of Merger - GlobeNewswire
Biotech Merger: Inmagene-Ikena Forms ImageneBio with $75M Backing from Elite Healthcare Investors - Stock Titan
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio - Investing.com
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company By Investing.com - Investing.com South Africa
iKena Oncology appoints Yarema as CEO of ImageneBio - TipRanks
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm - Investing.com
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology Stockholders Approve Merger With Inmagene Biopharmaceuticals - citybiz
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com India
Ikena Oncology Announces 1-for-12 Reverse Stock Split and Merger with Inmagene Biopharmaceuticals, to Trade as ImageneBio, Inc. on Nasdaq Under Ticker "IMA" - Nasdaq
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis - GlobeNewswire
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition - thebambooworks.com
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena - Endpoints News
Imagenebio Inc Stock (IMA) Financials Data
There is no financial data for Imagenebio Inc (IMA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.70%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):